| Phase 3 |
| NCT06927986 |
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated… |
EGFR-mutated Locally Advanced or Metastatic NSCLC |
Recruiting |
| NCT07230626 |
SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer |
Cervical Cancer |
Not Yet Recruiting |
| NCT07406542 |
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive… |
Recurrent or Metastatic Breast Cancer |
Not Yet Recruiting |
| NCT07417735 |
SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal… |
Locally Advanced/Metastatic/Recurrent ESCC |
Not Yet Recruiting |
| NCT07442565 |
SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ |
Non-Small Cell Lung Cancer |
Not Yet Recruiting |
| NCT07526792 |
SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial… |
Urothelial Carcinoma |
Not Yet Recruiting |
| NCT07376382 |
A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With… |
NSCLC |
Not Yet Recruiting |
| NCT07633873 |
SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for… |
Non-Small Cell Lung Cancer |
Not Yet Recruiting |
| NCT07672223 |
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in… |
Non-small Cell Lung Cancer |
Not Yet Recruiting |
| NCT07708753 |
A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or… |
Platinum-resistant Ovarian Cancer |
Not Yet Recruiting |
| NCT07758621 |
SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic… |
Head and Neck Squamous Cell Carcinoma |
Not Yet Recruiting |
| Phase 2/3 |
| NCT07251062 |
A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal… |
Esophageal Squamous Cell Carcinoma |
Not Yet Recruiting |
| Phase 2 |
| NCT07254585 |
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell… |
Head and Neck Squamous Cell Carcinoma |
Recruiting |
| NCT07597629 |
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer |
Advanced Breast Cancer |
Recruiting |
| NCT06989671 |
SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC |
Head and Neck Squamous Cell Carcinoma |
Not Yet Recruiting |
| NCT07256509 |
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant… |
Non-Small Cell Lung Cancer |
Not Yet Recruiting |
| NCT07354659 |
Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above |
Herpes Zoster |
Not Yet Recruiting |
| NCT07374549 |
SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma |
Advanced Urothelial Carcinoma |
Not Yet Recruiting |
| NCT07702656 |
A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in… |
High-grade Cervical Intraepithelial Lesions |
Not Yet Recruiting |
| NCT07714668 |
A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer |
Ovarian Cancer |
Not Yet Recruiting |
| Phase 1/2 |
| NCT07415863 |
Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors |
Advanced/Metastatic Solid Tumors |
Recruiting |
| NCT07744763 |
A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors |
Advanced Solid Tumors |
Recruiting |
| NCT06775236 |
Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other… |
Advanced Solid Tumors |
Not Yet Recruiting |
| NCT07122063 |
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary… |
Advanced Solid Tumors |
Active, Not Recruiting |
| NCT07622225 |
SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in… |
Advanced Solid Tumors |
Not Yet Recruiting |